TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Myocardial Perfusion Index (MPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean percentage of Ki-67-stained nuclei
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of cases with cells expressing Bcl-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: motivation for psychotherapy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: contacting a psychotherapist
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: arrhythmic death
Endpoint domain: Mortality/survival
Primary endpoint: all-cause ICD mortality
Endpoint domain: Mortality/survival
Primary endpoint: Global rank sum score of inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interleukin-6 (IL-6) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Simple Clinical Colitis Activity Index (SCCAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean change in NEI VFQ-25 composite score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: recurrence rate of recurrent respiratory infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: clinical effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Tumor involution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Late grade 3-4 morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Target lesion revascularization rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Target vessel revascularization rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Angiographic restenosis rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Taste of the contrast medium
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Upper airway CSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Primary spherical aberration (Z(4)(0))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-assessment manikin scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: tmax of MK-462
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: elevation in blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: serum growth hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Natriuresis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of neuropsychiatric symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Unfavorable outcome
Endpoint domain: Mortality/survival
Primary endpoint: Areas under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of cM-T412-coated CD4+ lymphocytes in SF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clear or almost clear of psoriasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of AAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating IGF-I levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of type 2 fibers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serious foot lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: social communication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: developmental level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adaptive behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of bactericidal antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric mean titers after vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety and reactogenicity profiles
Endpoint domain: Adverse events/effects
Primary endpoint: Wound spread (cm²)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alpha-band phase synchronization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of children with recurrent diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Decreased markers of intestinal inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: time to follow command
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flap failure
Endpoint domain: Adverse events/effects
Primary endpoint: Time to inhibit uterine contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of trauma
Endpoint domain: Adverse events/effects
Primary endpoint: time to pleurodesis failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BOLD activation to alcohol cues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean reduction of homocysteine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: UPDRS total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment-related adverse events (TRAE)
Endpoint domain: Adverse events/effects
Primary endpoint: RPD scores correlated with postural sway measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trait anxiety scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hair cross-section
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PEFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: V(50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 5-year event-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: 10-year overall survival estimates
Endpoint domain: Mortality/survival
Primary endpoint: Total hip BMD increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: HIV-1 plasma viral loads
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reinfection rate with H. pylori
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duodenal ulcer relapse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mortality of patients
Endpoint domain: Mortality/survival
Primary endpoint: RI levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RTOG/EORTC radiation dermatitis severity grades
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Erythema severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Subjective experience of itching and pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physical component of the FIM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isokinetic values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in anterior chamber cell grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients demonstrating complete clearing of anterior chamber cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean IOP increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Major deviation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to hypoglycaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: IPSS-QoL improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Seated trough diastolic BP control (< 90 mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Treatment-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: Risk of grade 3 or 4 hyperbilirubinemia
Endpoint domain: Adverse events/effects
Primary endpoint: Time to 0.8 TOF recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interval 25‐75% T1 recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance doses required
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Any adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: viral shedding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Objective MVPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma AGE-peptides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: clinically meaningful pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall acceptability scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Children's consumption of lunchbox fruit and vegetables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral blood flow velocity (CSvI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fear of progression/recurrence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean power during PT-1 and PT-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective 'readiness'
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of purulent conjunctivitis
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of purulent conjunctivitis due to bacterial infection
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of gram-positive bacteria
Endpoint domain: Adverse events/effects
Primary endpoint: Parent binge eating symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone microstructure organization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone volume density (BVVD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone mineral density (BMDlow)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean separation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rest-activity rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Neutralizing antibodies geometric mean titers (GMTs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immunity maintenance for 10 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Attention score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma CCK levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Crouch gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perception of body image
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: leukocyte values in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Scores on the knowledge test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: effective rate of analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: excellent rate of analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probing for contextual issues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Developing appropriate treatment plans for contextual issues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FSR of fibrinogen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rates of decline in striatal binding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Urinary isoflavone excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Isoflavone intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: VAS fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: VAS capability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Posttraumatic growth levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Resilience levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: headache freedom at 30 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reproductive knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intention to delay childbearing
Endpoint domain: Life impact
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: oral area under the serum concentration‐time curve (AUC) of lovastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum serum concentration (Cmax) of lovastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in hematocrit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: confidence to exercise
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Development of pressure sores
Endpoint domain: Adverse events/effects
Primary endpoint: dynamic pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IV morphine use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in functional scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in plasma total cholesterol (TC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in HDL cholesterol (HDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cardiac events (cardiac death, unstable angina, non-fatal reinfarction)
Endpoint domain: Mortality/survival
Primary endpoint: Aortic stiffness (PWV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reaction time for memory task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: percentage of daily energy needs consumed from snack-foods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in bone mineral density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal handling of uric acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: joint mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to exercise therapy
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: weekly time in MVPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of PA per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence of SVT requiring medical intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean duration of PO higher than 0.3 s
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of PO higher than 0.3 s
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean duration of the longest PO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive end expiratory pressure levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in cholesterol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Risk of stroke (fatal plus nonfatal)
Endpoint domain: Mortality/survival
Primary endpoint: Risk of fatal stroke
Endpoint domain: Mortality/survival
Primary endpoint: Agreement between dynamic retinoscopy and open-field autorefraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in clinical blood lipid biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Levels of IgA, IgM, and IgG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Subjective daytime sleepiness
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: percentage change in heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percentage change in systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Episodes of pause-dependent polymorphic VT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of TdP
Endpoint domain: Adverse events/effects
Primary endpoint: Hematologic toxicity (grade 3 or 4)
Endpoint domain: Adverse events/effects
Primary endpoint: Suppression of platelet activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minor bleeding rates
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean body weight reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Normal level of magnesium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Beck score reduction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Umbilical cord serum 25‐OH vit D concentrations at delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean maternal serum 25‐OH Vit D concentrations at delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intervertebral Foramen Height (IPH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of endoleaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delivery within 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Delay to the onset of eating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short-term negative energy balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Long-term VAS back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in STAIC-trait scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Abstinence following treatment for nicotine dependence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Peak-effort dyspnea (D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health-related quality of life (SGRQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean EBC nitrite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sum of nitrite and nitrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pearl Indices
Endpoint domain: Mortality/survival
Primary endpoint: 1-year cumulative pregnancy rates
Endpoint domain: Mortality/survival
Primary endpoint: scheduled bleeding frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: achievement of 10% weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Response to lithium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum protein concentration after plasmapheresis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colloid oncotic pressure before and after exchange
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost of substitution solutions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Interfacial bond strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the curve of plasma insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes